United States Today

Physicians see 2.5 million patients per day in the US alone. In over 60% of those visits, the physician needs to order diagnostic tests to guide treatment or monitoring of their patient. Traditionally, a physician sends a patient sample  to a reference lab and waits 1-5 days for the results. Because physicians lack an affordable technology to deliver real time, lab quality results, the physician is either forced to make decisions without the information they need, or schedule the patient for a second visit. This process is slow, inefficient, and penalizes the patient with suboptimal care, and the physician with the burden of overhead associated with two patient contacts, yet with reimbursement for only one visit. In this healthcare model, the biggest winner is the reference lab that captures all the testing revenue.

Global Healthcare Today

Healthcare in India, China, Africa, Eastern Europe and South America all have one thing in common: healthcare services are anchored in centralized locations and are available only to those who have geographic and financial access. The underserved healthcare population throughout the world is immense. In the rare cases that patients do gain access to treatment, they often travel many miles to central labs located miles from the nearest towns. The critical need for an affordable, easy to use by low skilled labor; diagnostic technology that can be distributed throughout each country remains a well-documented unmet need. Developing countries with  minimal legacy healthcare infrastructure in place are fertile and receptive markets for the application of a robust, enabling, and most importantly, low cost technology solution. These emerging healthcare systems have the highest annual growth for diagnostic technologies in the world and are projected to remain so for the foreseeable future.


Parallax is focused primarily on serving the multi-billion outpatient Infectious Disease testing market with a platform that combines reference laboratory quality, real time results in the doctor's office and a menu of most commonly ordered tests. Reference labs do not have the infrastructure to cost effectively provide immediate results to physicians. Alternative Point of Care (POC) products are limited in scope, too expensive or too complex for wide-scale adoption. The Parallax system, however, is a technology-enabled system to improve patient outcome and improve physician office efficiency. As compared to reference labs or POC alternatives, Parallax Target System can deliver a combination of benefits not possible in any other solution.

The Parallax Point of Care Target System diagnostic system has a unique, Micro-Flow enzyme-linked immunosorbent assay (ELISA) technology that when applied to critical diagnostic tests can transform the way global healthcare is provided. This technology allows Parallax to put a large number of reference lab quality diagnostic tests in the hands of global healthcare providers in the locations where they care for their patients. The Company is focused on tests that detect or monitor infectious diseases. Reference lab quality, real time, easy to use, and low cost diagnostic testing lets physicians treat their patients in one visit. Parallax’s Target System will improve patient care and physician practice efficiency.

Parallax Target System Platform will unlock the potential of POC testing. This USPTO and International Patent Pending technology and process platform has the potential to transform global healthcare by providing a completely integrated solution that puts critical infectious disease diagnostic testing in the hands of the healthcare provider in real time. The results will dramatically improve patient care and physician practice efficiency.